Kopran Limited (KOPRAN) AI Stock Analysis

• Market Cap: ₹8.18B
• Dividend Yield: 1.77%
• Average Volume (3M): 15.15K
• Price to Earnings (P/E): 23.4
• Beta (1Y): 1.13
• Revenue Growth: -1.83%
• EPS Growth: -41.16%
• Country: IN
• Employees: 842
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.54
• Shares Outstanding: 48,285,606
• 10 Day Avg. Volume: 8,585
• 30 Day Avg. Volume: 15,150
• PEG Ratio: -0.96
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 1.44
• P/FCF Ratio: -67.21
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ₹182.00 ▲(9.37% Upside)

Kopran Limited's overall stock score reflects strong financial performance with revenue growth and operational efficiency. However, challenges in cash flow conversion and a moderate valuation limit the upside potential. Technical indicators suggest mixed momentum, with short-term weakness but medium-term support.

Kopran Limited Business Overview & Revenue Model

Company Description

Kopran Limited (KOPRAN) is a pharmaceutical company based in India, primarily engaged in the manufacture and marketing of a wide range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and specialty chemicals. The company operates in various therapeutic segments, including but not limited to, cardiovascular, anti-infective, and anti-diabetic drugs. Kopran's commitment to quality and innovation is reflected in its extensive product portfolio, catering to both domestic and international markets.

How the Company Makes Money

Kopran generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and APIs. The company has established a strong presence in both the domestic and export markets, leveraging its manufacturing capabilities to produce a diverse range of products. Key revenue sources include direct sales to healthcare providers, hospitals, and pharmacies, as well as partnerships with other pharmaceutical companies for contract manufacturing and distribution. Additionally, Kopran capitalizes on regulatory approvals to expand its product offerings and enter new markets, which enhances its revenue potential. Strategic alliances and collaborations with international firms also contribute to its earnings, allowing for broader market access and increased sales volume.

Kopran Limited Financial Statement Overview

Summary

Kopran Limited shows strong revenue growth and operational efficiency improvements. The balance sheet indicates a robust equity position and prudent debt management, but challenges remain in converting profits to free cash flow. Overall, the company is on a growth trajectory with potential for further strengthening profitability and cash flow management.

Income Statement

Kopran Limited has demonstrated steady revenue growth with a notable increase from 2024 to 2025, showing a revenue growth rate of 3.2%. The gross profit margin for 2025 is 35.7%, reflecting efficient cost management. However, net profit margin declined to 6.1% in 2025 from 8.4% in 2024, indicating pressure on net profitability despite higher revenues. The EBIT margin improved significantly to 26.1% in 2025, suggesting enhanced operational efficiency. EBITDA margin decreased slightly to 11.6% in 2025, indicating some challenges in maintaining earnings before amortization and depreciation.

Balance Sheet

The balance sheet reveals a solid equity base, with equity ratio improving to 61.4% in 2025, indicating strong capitalization. The debt-to-equity ratio is 0.29, reflecting prudent leverage. However, the return on equity has decreased to 7.4% in 2025 from 10.4% in 2024, highlighting challenges in generating returns from equity. The overall stability is strong, but there is room for improvement in leveraging equity more effectively.

Cash Flow

Kopran Limited faces challenges in cash flow management, with free cash flow remaining negative in 2025 despite operating cash flow being positive. The free cash flow to net income ratio is -0.35, indicating inefficiencies in converting profits into free cash flows. The operating cash flow to net income ratio is 1.09, suggesting that operating cash flow supports net income, but capital expenditures weigh heavily on free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.25B	6.30B	6.15B	5.48B	4.74B	4.81B
Gross Profit	2.21B	2.25B	2.09B	1.86B	1.90B	1.67B
EBITDA	695.48M	729.00M	868.18M	548.77M	980.11M	997.82M
Net Income	349.06M	385.52M	509.56M	272.33M	610.31M	616.06M
Balance Sheet
Total Assets	0.00	8.44B	7.43B	6.50B	6.11B	4.39B
Cash, Cash Equivalents and Short-Term Investments	258.64M	258.64M	80.91M	73.97M	58.68M	9.35M
Total Debt	0.00	1.48B	992.28M	752.38M	745.49M	663.02M
Total Liabilities	-5.18B	3.26B	2.52B	2.10B	1.85B	1.94B
Stockholders Equity	5.18B	5.18B	4.91B	4.39B	4.26B	2.45B
Cash Flow
Free Cash Flow	0.00	-134.46M	-133.56M	-270.22M	-757.47M	355.37M
Operating Cash Flow	0.00	419.42M	432.58M	340.23M	-334.75M	599.51M
Investing Cash Flow	0.00	-564.28M	-435.52M	-126.50M	-844.15M	-252.79M
Financing Cash Flow	0.00	258.68M	9.88M	-198.44M	1.23B	-345.71M

Kopran Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 166.40
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Neutral. The current price of 166.4 is below the 20-day moving average (MA) of 172.97, below the 50-day MA of 168.89, and below the 200-day MA of 178.22, indicating a neutral trend. The MACD of -1.14 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 28.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KOPRAN.

Kopran Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KILITCH	64 Neutral	₹6.56B	22.02	―	―	37.51%	122.52%
SAKAR	64 Neutral	₹7.72B	39.03	―	―	21.65%	73.16%
KOPRAN	61 Neutral	₹8.18B	23.45	―	1.77%	-1.83%	-41.16%
WANBURY	58 Neutral	₹7.50B	17.40	―	―	12.37%	-17.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kopran Limited Corporate Events

Kopran Limited Announces Board Changes

Kopran Limited has announced changes in its Board of Directors, with Mr. Siddhan Subramanian and Mrs. Sunita Banerji completing their terms as Non-Executive Independent Directors as of September 17, 2025. This change reflects the company’s adherence to regulatory requirements and may impact its governance structure, potentially influencing stakeholder confidence.